The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer

• Published in: Clinical science (1979) Vol. 136; no. 3; pp. 197 - 222
• Main Authors: Cunningham, Richard, Hansen, Carsten Gram
• Format: Journal Article
• Language: English
• Published: England Portland Press Ltd 01.02.2022
• Subjects: Animals; Cancer; Carcinogenesis; Cell Cycle, Growth & Proliferation; Cell Homeostasis & Autophagy; Gene Expression & Regulation; Hippo Signaling Pathway; Humans; Immunology & Inflammation; Metabolism; Neoplasms - drug therapy; Neoplasms - metabolism; Pharmacology & Toxicology; Review; Signaling; Stem Cells; Trans-Activators; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins; Translational Science; YAP-Signaling Proteins; Mesothelioma; Hippo pathway; Sarcoma; Immuno-oncology; AlphaFold; Cancer
• ISSN: 0143-5221; 1470-8736; 1470-8736
• DOI: 10.1042/CS20201474

Tumorigenesis is a highly complex process, involving many interrelated and cross-acting signalling pathways. One such pathway that has garnered much attention in the field of cancer research over the last decade is the Hippo signalling pathway. Consisting of two antagonistic modules, the pathway plays an integral role in both tumour suppressive and oncogenic processes, generally via regulation of a diverse set of genes involved in a range of biological functions. This review discusses the history of the pathway within the context of cancer and explores some of the most recent discoveries as to how this critical transducer of cellular signalling can influence cancer progression. A special focus is on the various recent efforts to therapeutically target the key effectors of the pathway in both preclinical and clinical settings.